|By PR Newswire||
|August 27, 2014 08:41 PM EDT||
LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Co-development Terms & Agreements in Pharma, Biotech and Diagnostics
The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter co-development deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of co-development dealmaking and business activities.
The initial chapters of this report provide an orientation of co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-development as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of co-development deals. The chapter includes numerous case studies to enable understanding of both pure co-development deals and multicomponent deals where co-development forms a part.
Chapter 4 provides a review of the leading co-development deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive review of co-development financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.
Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of co-development deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 8 provides a comprehensive and detailed review of co-development deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about co-development as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.
Co-development Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.
Co-development Terms and Agreements in Pharma, Biotech and Diagnostics includes:
Trends in co-development dealmaking in the biopharma industry since 2009
Analysis of co-development deal structure
Case studies of real-life co-development deals
Comprehensive listing of co-development deals since 2009
Access to co-development contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading co-development deals by value since 2009
Most active co-development dealmakers since 2009
The leading co-development partnering resources
In Co-development Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Chapter 1 – Introduction
Chapter 2 – Trends in co-development dealmaking
2.2. Definition of co-development deals
2.3. Success factors for co-development deals
2.4. When co-development can be useful
2.5. Attributes of co-development deals
2.6. Aligning partners to make the co-development work
2.7. Trends in co-development deals since 2009
2.8. Option to co-develop
2.9. The future of co-development deals
Chapter 3 – Overview of co-development deal structure
3.2. Pure versus multi-component co-development deals
3.3. Pure co-development agreement structure
3.3.1. Example co-development agreements
3.3.1.a. Case study 1: Ambrx – Zhejiang Medicine – June 2013
3.3.1.b. Case study 2: UniQure - Chiesi – July 2013
Chapter 4 – Leading co-development deals
4.2. Top co-development deals by value
4.3. Most active co-development dealmakers
4.4. Bigpharma co-development deal activity
Chapter 5 – Bigpharma co-development deals
5.2. How to use co-development deals
5.3. Company co-development agreement listings
Chapter 6 – Bigbiotech co-development deals
6.2. How to use co-development deals
6.3. Company co-development agreement listings
Chapter 7 – Co-development contract directory 2009-2014
7.2. Company A-Z
7.3. By therapy area
Central Nervous System
7.4. By stage of development at signing
7.5. By technology area
Appendix 1 – Co-development references
Appendix 2 – Resources
Appendix 3 – Deal type definitions
About Wildwood Ventures
Order Form – Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form – Reports
Separate appendix file supplied for:
Appendix 1 – Co-development dealmaking - by financial disclosure
Appendix 2 – Co-development dealmaking - by companies A-Z
Appendix 3 – Co-development dealmaking - by stage of development
Appendix 4 – Co-development dealmaking - by therapeutic target
Appendix 5 – Co-development dealmaking - by technology type
TABLE OF FIGURES
Figure 1: Definition of co-development
Figure 2: Situations where co-development can prove useful
Figure 3: Key components of a co-development deal
Figure 4: Issues in implementing co-development agreements
Figure 5: Trends in co-development deal announcements, 2009-2014
Figure 6: Co-development deals signed at each phase of development, 2009-2013
Figure 7: Co-development agreements – what should a contract include?
Figure 8: Components of the co-development deal structure
Figure 9: Top co-development deals by value since 2009
Figure 10: Most active co-development dealmakers 2009-2014
Figure 11: Bigpharma – top 50 – Co-development deals 2007 to 2013
Figure 12: Bigpharma co-development deal frequency - 2009 to 2014
Figure 13: Online partnering resources
Figure 14: Deal type definitions
Read the full report:
Co-development Terms & Agreements in Pharma, Biotech and Diagnostics
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Apr. 25, 2017 10:30 PM EDT Reads: 1,831
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Apr. 25, 2017 10:30 PM EDT Reads: 575
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Apr. 25, 2017 10:30 PM EDT Reads: 7,107
Apr. 25, 2017 10:15 PM EDT Reads: 1,156
Apr. 25, 2017 10:15 PM EDT Reads: 1,269
Apr. 25, 2017 10:00 PM EDT Reads: 3,690
Apr. 25, 2017 09:45 PM EDT Reads: 1,241
Apr. 25, 2017 08:30 PM EDT Reads: 2,490
Apr. 25, 2017 08:15 PM EDT Reads: 490
Apr. 25, 2017 07:45 PM EDT Reads: 1,751
Apr. 25, 2017 07:15 PM EDT Reads: 3,101
Apr. 25, 2017 06:15 PM EDT Reads: 2,187
Apr. 25, 2017 06:15 PM EDT Reads: 1,154
Apr. 25, 2017 06:15 PM EDT Reads: 338
Apr. 25, 2017 06:15 PM EDT Reads: 961